NCT01075971View on ClinicalTrials.gov

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Opioid Dependency
Interventions
DRUG

Buprenorphine hydrochloride marketed sublingual tablet (Subutex)

8 mg or 16 mg daily, sublingual route on Days 1 and 2

DRUG

Buprenorphine hydrochloride fast dissolving tablet (FDT)

8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
collaborator

Reckitt Benckiser LLC

INDUSTRY

lead

Indivior Inc.

INDUSTRY

NCT01075971 - Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED) | Biotech Hunter | Biotech Hunter